Modality
mAb
MOA
AuroraAi
Target
B7-H3
Pathway
T-cell
CF
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
Jan 2021
→ Oct 2031
Phase 2Current
NCT05296290
736 pts·CF
2022-03→2028-06·Active
NCT04498991
44 pts·CF
2021-01→2031-10·Recruiting
780 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-06-212.2y awayPh2 Data· CF
2031-10-245.6y awayPh2 Data· CF
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Recruit…
P2
Active
Catalysts
Ph2 Data
2028-06-21 · 2.2y away
CF
Ph2 Data
2031-10-24 · 5.6y away
CF
RecruitingActive|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ |